Tetrabenazine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tetrabenazine: From Huntington's Disease Chorea to Polycystic Kidney Disease 3
One-Sentence Summary
Tetrabenazine is a VMAT2 (vesicular monoamine transporter 2) inhibitor historically used to control chorea in Huntington's disease; formal original-indication and licensing data are not present in this evidence pack (original_indications empty, original_moa marked as Data Gap). TxGNN predicts potential efficacy in Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease) with a 99.90% score, but this is supported by zero clinical trials and 20 background literature items that discuss the disease itself, not the drug-disease relationship. The drug's own repurposing rationale flags this as a likely graph-topology artifact rather than a mechanistically grounded hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from formal licensing data (no NZ market authorization on file); drug class context (VMAT2 inhibitor / monoamine-depleting agent) points to Huntington's disease chorea management |
| Predicted New Indication | Polycystic Kidney Disease 3, with or without Polycystic Liver Disease |
| TxGNN Prediction Score | 99.90% (rank 1353) |
| Evidence Level | L5 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available for this evaluation (original_moa = Data Gap). The evidence pack's own repurposing rationale, however, notes that tetrabenazine acts as a VMAT2 inhibitor, depleting presynaptic monoamines (dopamine, serotonin, norepinephrine) — a pathway used therapeutically to suppress chorea and other hyperkinetic movement symptoms.
Polycystic Kidney Disease 3 and polycystic liver disease arise from a fundamentally different biology: mutations affecting primary cilia function and cyst-related genes (e.g., PKD1, PKD2, PKHD1), driving progressive cystogenesis in the kidney and liver. There is no established pharmacological or physiological link between monoamine vesicular transport and ciliopathy-driven cyst formation.
The evidence pack's own assessment is explicit on this point: the high TxGNN score most likely reflects graph co-occurrence or topological similarity within the knowledge graph rather than genuine mechanistic support. This prediction should be treated as a hypothesis-generation signal only, not as evidence of biological plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
None of the retrieved literature discusses tetrabenazine directly — all 20 items describe the biology, diagnosis, or management of polycystic kidney/liver disease in general, with no drug-specific findings. The top entries by type priority are listed below.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38958301 | 2024 | Review/Guideline | Am J Gastroenterol | ACG guideline on focal liver lesions, including polycystic liver disease management |
| 35728731 | 2022 | Guideline | J Hepatol | EASL clinical practice guidelines on cystic liver diseases |
| 30819518 | 2019 | Review | Lancet | Overview of autosomal dominant polycystic kidney disease (ADPKD) pathophysiology and management |
| 35487607 | 2022 | Review | Clin Liver Dis | Clinical course of ADPKD and associated polycystic liver disease (PLD) |
| 29038287 | 2018 | Review | JASN | Genetic overlap and shared pathogenesis between ADPKD and ADPLD |
| 38097330 | 2023 | Review | Adv Kidney Dis Health | Genetic spectrum of PKD1/PKD2 mutations and resulting phenotypes |
| 34034501 | 2022 | Review | Rev Esp Enferm Dig | Diagnosis and management of liver hydatid cyst (differential diagnosis context) |
| 36047551 | 2022 | Review | Rev Med Suisse | Overview of polycystic liver disease subtypes and clinical course |
| 37266470 | 2023 | Case Report | Maedica | Rare case of ADPKD/PLD associated with advanced gastric cancer |
| 40296340 | 2025 | Cohort | Ann Transplant | Outcomes of combined liver-kidney transplantation in 9 PLD/PKD patients |
New Zealand Market Information
No New Zealand market authorization is currently on file — tetrabenazine is not marketed in New Zealand under this evidence pack's data (0 licenses).
Safety Considerations
Please refer to the package insert for safety information. Note: the TFDA/Medsafe package insert (warnings/contraindications) is flagged in this evidence pack as a Blocking data gap (DG001), meaning a formal safety pre-screen (S1) cannot currently be completed for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported only by the TxGNN model score (L5, no clinical trials, no drug-specific literature), and the evidence pack's own mechanistic analysis concludes there is no known biological link between VMAT2 inhibition and cystic kidney/liver disease pathogenesis — the high score is more likely a graph-topology artifact than a genuine repurposing signal. This is also the strongest-evidenced candidate among the 10 predicted indications for tetrabenazine in this pack; ranks 2–10 have no clinical trials and little to no literature at all, and several (e.g., thoracic malformation, rank 5) rely on tangential or unrelated evidence.
To proceed, the following is needed:
- TFDA/Medsafe package insert data to resolve the Blocking safety gap (DG001)
- Confirmed original indication and mechanism of action (DrugBank MOA currently a Data Gap, DG002)
- Preclinical or mechanistic studies directly linking VMAT2/monoamine pathways to ciliopathy-driven cystogenesis, if such a hypothesis is to be pursued further
- Drug-specific clinical or case evidence connecting tetrabenazine to renal/hepatic cystic disease outcomes
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.